Broadfin Capital’s Integra LifeSciences IART Stock Holding History

Broadfin Capital’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-141,572	Closed	-$7.89M	–	42
2019 Q1	$7.89M	Sell	141,572 -55,000	-28%	-$2.8M	1.63%	27
2018 Q4	$8.87M	Hold	196,572	–	–	1.17%	26
2018 Q3	$12.9M	Buy	196,572 +33,148	+20%	+$2.06M	1.91%	19
2018 Q2	$10.5M	Sell	163,424 -135,000	-45%	-$8.36M	1.66%	23
2018 Q1	$16.5M	Sell	298,424 -32,176	-10%	-$1.69M	2.57%	14
2017 Q4	$15.8M	Buy	330,600 +252,100	+321%	+$12.3M	2.59%	18
2017 Q3	$3.96M	Buy	+78,500	New	+$4.03M	0.59%	37
2013 Q4	–	Sell	-541,627	Closed	-$8.91M	–	64
2013 Q3	$8.91M	Sell	541,627 -688,738	-56%	-$11.1M	1.58%	20
2013 Q2	$18.4M	Buy	+1,230,365	New	+$18M	3.6%	10

Other funds holding IART

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Broadfin Capital's IART Position: Q2 2019 in Review

Broadfin Capital sold out of Integra LifeSciences (IART) in Q2 2019, closing a stake of 141,572 shares — an estimated $7.89M sold.

Broadfin Capital first reported a position in IART in Q2 2013 and held it in 9 quarters. The position peaked at $18.4M in Q2 2013. 262 funds tracked by Wall St. Rank hold IART as of Q2 2019.

Broadfin Capital reported no remaining Integra LifeSciences position as of Q2 2019 after selling out during the quarter.
Broadfin Capital sold 141,572 Integra LifeSciences shares in Q2 2019, an estimated $7.89M.
Broadfin Capital first reported a position in Integra LifeSciences in Q2 2013 and held it in 9 quarters.
Broadfin Capital's Integra LifeSciences position peaked at $18.4M in Q2 2013.
262 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2019.

Based on Broadfin Capital's 13F filing for Q2 2019, filed 14 Aug 2019.